• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向治疗和生物治疗时代类风湿关节炎和银屑病关节炎的感染并发症:2020 年的观点。

Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.

机构信息

Paris University, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, IHU Imagine, Necker Enfants malades University Hospital, APHP, Paris, France

Institut Pasteur, National Reference Center for Invasive Mycoses and Antifungals, Molecular Mycology Unit, CNRS UMR 2000, Paris, France.

出版信息

Ann Rheum Dis. 2020 Dec;79(12):1532-1543. doi: 10.1136/annrheumdis-2020-217092. Epub 2020 Sep 22.

DOI:10.1136/annrheumdis-2020-217092
PMID:32963049
Abstract

Biological therapies have improved the outcomes of several major inflammatory, autoimmune and also neoplastic disorders. Those directed towards cytokines or other soluble mediators, cell-surface molecules or receptors or various components of intracellular signalling pathways may be associated with the occurrence of infections whose diversity depends on the particular immune target. In this context and following a keynote lecture given by one of us at the European League Against Rheumatism meeting on June 2018, a multidisciplinary group of experts deeply involved in the use of targeted and biological therapies in rheumatoid and psoriatic arthritis decided to summarise their recent vision of the immunological basis and epidemiology of infections occurring during targeted and biological therapies, and provide useful indications for their management and prevention.

摘要

生物疗法改善了多种主要炎症性、自身免疫性和肿瘤性疾病的预后。针对细胞因子或其他可溶性介质、细胞表面分子或受体或细胞内信号通路的各种成分的生物疗法可能与感染的发生有关,感染的多样性取决于特定的免疫靶点。在这方面,继我们中的一位在 2018 年 6 月举行的欧洲抗风湿病联盟会议上发表主题演讲后,一个由在类风湿关节炎和银屑病关节炎中使用靶向和生物疗法方面具有深入经验的多学科专家小组决定总结他们对靶向和生物疗法期间发生的感染的免疫学基础和流行病学的最新观点,并提供有关其管理和预防的有用建议。

相似文献

1
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.靶向治疗和生物治疗时代类风湿关节炎和银屑病关节炎的感染并发症:2020 年的观点。
Ann Rheum Dis. 2020 Dec;79(12):1532-1543. doi: 10.1136/annrheumdis-2020-217092. Epub 2020 Sep 22.
2
Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs.类风湿关节炎和银屑病关节炎患者在接受联合使用改善病情抗风湿药物治疗时的阿达木单抗谷浓度。
Ann Rheum Dis. 2015 Feb;74(2):474-5. doi: 10.1136/annrheumdis-2014-206588. Epub 2014 Nov 28.
3
First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.2002年至2011年类风湿关节炎、银屑病关节炎和轴性脊柱关节炎中生物性改善病情抗风湿药物的首次处方:来自北欧改善病情抗风湿药物登记处的数据
Ann Rheum Dis. 2014 Oct;73(10):1905-6. doi: 10.1136/annrheumdis-2014-205490. Epub 2014 Jul 2.
4
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).非甾体抗炎药(包括阿司匹林和对乙酰氨基酚)在接受甲氨蝶呤治疗炎性关节炎(类风湿关节炎、强直性脊柱炎、银屑病关节炎、其他脊柱关节炎)患者中的安全性。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD008872. doi: 10.1002/14651858.CD008872.pub2.
5
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.英国风湿病学会关于炎性关节炎生物改善病情抗风湿药的安全指南。
Rheumatology (Oxford). 2019 Feb 1;58(2):e3-e42. doi: 10.1093/rheumatology/key208.
6
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.中文学术文献翻译
Ann Rheum Dis. 2020 Jun;79(6):778-786. doi: 10.1136/annrheumdis-2020-217163. Epub 2020 May 7.
7
Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.德国接受皮下生物制剂治疗的类风湿病(类风湿关节炎、强直性脊柱炎、银屑病关节炎)患者的治疗持续性。
Rheumatol Int. 2016 Jan;36(1):143-53. doi: 10.1007/s00296-015-3348-4. Epub 2015 Aug 28.
8
Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis.类风湿关节炎和银屑病关节炎中生物靶向改善病情抗风湿药物联合治疗的理由、现状和机遇。
Joint Bone Spine. 2023 Sep;90(5):105578. doi: 10.1016/j.jbspin.2023.105578. Epub 2023 Apr 17.
9
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary.英国风湿病学会炎症性关节炎生物性改善病情抗风湿药安全指南——执行摘要
Rheumatology (Oxford). 2019 Feb 1;58(2):220-226. doi: 10.1093/rheumatology/key207.
10
Useful message in choosing optimal biological agents for patients with autoimmune arthritis.选择自身免疫性关节炎患者最佳生物制剂的有用信息。
Biochem Pharmacol. 2019 Jul;165:99-111. doi: 10.1016/j.bcp.2019.03.007. Epub 2019 Mar 13.

引用本文的文献

1
Risk of Serious Infections in Patients Treated With Biologic or Targeted-synthetic Disease Modifying Antirheumatic Drugs in Qatar.卡塔尔接受生物制剂或靶向合成改善病情抗风湿药物治疗的患者发生严重感染的风险
Immun Inflamm Dis. 2025 Apr;13(4):e70195. doi: 10.1002/iid3.70195.
2
Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis.具有双功能抗炎作用的抗体-药物偶联物在类风湿关节炎发病机制中的治疗潜力
Arthritis Res Ther. 2024 Dec 19;26(1):216. doi: 10.1186/s13075-024-03452-0.
3
Infections in psoriatic arthritis: association with treatment.
银屑病关节炎中的感染:与治疗的关联。
Ther Adv Musculoskelet Dis. 2024 Oct 16;16:1759720X241289201. doi: 10.1177/1759720X241289201. eCollection 2024.
4
Dendritic cells transfected with DNA constructs encoding CCR9, IL-10, and type II collagen demonstrate induction of immunological tolerance in an arthritis model.经 DNA 构建体转染的树突状细胞编码 CCR9、IL-10 和 II 型胶原在关节炎模型中显示诱导免疫耐受。
Front Immunol. 2024 Aug 5;15:1447897. doi: 10.3389/fimmu.2024.1447897. eCollection 2024.
5
Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.合并症和特殊人群的中重度特应性皮炎患者的生物制剂和小分子治疗:意大利视角
Dermatol Reports. 2023 Sep 13;16(2):9839. doi: 10.4081/dr.2023.9839. eCollection 2024 Jun 14.
6
Inhibition of LSD1 via SP2509 attenuated the progression of rheumatoid arthritis.通过 SP2509 抑制 LSD1 可减轻类风湿关节炎的进展。
Immunol Res. 2024 Aug;72(4):797-810. doi: 10.1007/s12026-024-09486-5. Epub 2024 May 9.
7
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS).不同类别靶向治疗药物用于治疗银屑病关节炎相关严重感染风险:来自法国健康保险数据库(SNDS)的全国性队列研究。
RMD Open. 2024 Mar 14;10(1):e003865. doi: 10.1136/rmdopen-2023-003865.
8
Construction of shared gene signature between rheumatoid arthritis and lung adenocarcinoma helps to predict the prognosis and tumor microenvironment of the LUAD patients.类风湿性关节炎和肺腺癌之间共享基因特征的构建有助于预测肺腺癌患者的预后和肿瘤微环境。
Front Mol Biosci. 2024 Jan 10;10:1314753. doi: 10.3389/fmolb.2023.1314753. eCollection 2023.
9
Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.银屑病关节炎的管理:风湿病专家的共识意见
Front Med (Lausanne). 2023 Nov 30;10:1327931. doi: 10.3389/fmed.2023.1327931. eCollection 2023.
10
[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].[基础疾病和免疫抑制对炎性风湿性疾病免疫能力的影响]
Z Rheumatol. 2024 Mar;83(2):87-97. doi: 10.1007/s00393-023-01408-4. Epub 2023 Aug 29.